←
Jason Sicklick539 posts
Jason Sicklick avatar✓

Jason Sicklick ✓

@JasonSicklick

Professor of Surgery & Pharmacology at UC San Diego. Surgical Oncologist. Surgeon-Scientist. Exec VC of Research. “Views expressed are my own personal beliefs”

◷ Joined January 2018▧ 64 Photos and videos
Vivek Subbiah, MD avatar
⟳ Jason Sicklick retweeted
Vivek Subbiah, MD@VivekSubbiah·Oct 9

🚨⭐️HOT OFF THE PRESS👉Pleased to share our new paper, led by the amazing @JulianaRBeal @niamhjcoleman @JiaJennyLiu 👉Precision before incision: neoadjuvant tumor-agnostic therapies.” 👉Nine tumor-agnostic drugs now have a case for earlier use, before resistance sets in and with organ preservation in mind. 👉A PD-1 blockade hit a 100% complete response in MMR-deficient rectal cancer. 🧬 @JasonSicklick @OncoAlert @oncodaily cell.com/trends/cancer/abstr… #PrecisionOncology

Post attachment
Diane M. Simeone, MD avatar
⟳ Jason Sicklick retweeted
Diane M. Simeone, MD@MadameSurgeon·Oct 2

Moores Cancer Center at UC San Diego Health has transformed its clinical trials enterprise, becoming a leader in innovative clinical trial design. STRIPe (STudy of Real-world Individualized Precision-oncology) is a powerful example of this progress — the first randomized precision oncology trial of its kind, testing personalized, molecularly matched treatment strategies against standard-of-care therapy for patients with advanced cancers. Learn more: bit.ly/4rKmGWG

Post attachment
OncLive.com avatar
⟳ Jason Sicklick retweeted
OncLive.com@OncLive·Jun 29

A 4-line standard has held for 6 years in advanced GIST. Now PEAK phase 3 data on bezuclastinib plus sunitinib is changing the conversation: PFS 16.5 vs 9.2 months (HR 0.50, P<.0001) and ORR nearly doubled. Sarcoma experts break down what comes next. Watch the full episodes: hubs.li/Q04mnH2t0 (hubs.li/Q04mnCg50) @JasonSicklick @UCSDsurgery @AgulnikMd @CityofHope @NeetaSomaiahMD @UTMDAnderson @immunosarc @NorthwesternMed #GIST #SarcomaSmSurg #PrecisionOncology

Post attachment
UC San Diego Surgery avatar
⟳ Jason Sicklick retweeted
UC San Diego Surgery@UCSDsurgery·May 13

Yesterday, we held our 14th Annual #UCSDSurgery Research Symposium! The night included 101 presentations and a thoughtful talk on recent pediatrics research by David Hackam, MD, PhD. A huge thank you to all of our presenters and attendees!

0:23
Vivek Subbiah, MD avatar
⟳ Jason Sicklick retweeted
Vivek Subbiah, MD@VivekSubbiah·Mar 16

🚨Hot off the press👉Pleased to share my new commentary: "Matching hallmarks of cancer complexity with N-of-1 precision oncology" 🧬 @MedCellPress 👉A viewpoint on the latest iteration of Doug Hanahan's Hallmarks of Cancer framework and @Dr_R_Kurzrock 's the i-PREDICT trial, and what they mean together for #precisionmedicine 👉What is #PrecisionOncology 's E=MC2 ? Tweetorial soon. @OncoAlert @MedwatchKate @OpenMedicineHQ @oncodaily @Aiims1742 @neerajaiims @weldeiry @chadinabhan Free @CellPressNews link for 50 days authors.elsevier.com/a/1mm2C…

Post attachment
Razelle Kurzrock, MD avatar
⟳ Jason Sicklick retweeted
Razelle Kurzrock, MD@Dr_R_Kurzrock·Jan 16

Thanks. Such a pleasure to work with TargetCancer on the TRACK study, a one of a kind decentralized n-of-1 rare cancer trial built on the I-PREDICT model @VivekSubbiah